Oaktree Acquisition II scheduled a June 7 meeting for shareholders to vote on its proposed merger with Alvotech Holdings, a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines.
As announced in December, the combination is expected to deliver gross proceeds to Alvotech in excess of $450 million.
The deal has an implied enterprise value of $2.25 billion.
If approved, the combined company is expected to trade on the Nasdaq under ALVO. Read more.
